Piramal Pharma Limited has informed the Exchange about update on litigation

Nclt Resolution ApprovedRegulatory & Legal View source PDF Explain this filing

PPLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.6%Reaction day

₹203.60

prior close

₹204.70

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.2%-0.4% vs market

Pharmaceuticals peers, median of 150sector-0.4%-0.2% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty Smallcap 250 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.5

15m

-0.3

30m

-0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.6-0.2-0.4-0.4-0.2

Next day

-1.1-0.4-0.7-0.9-0.2

-0.8+0.1-0.9-0.6-0.2

-1.4+0.0-1.4-0.9-0.4

-1.3-0.7-0.6-1.1-0.2

+2.3+0.3+2.0-0.3+2.6

+5.4+1.2+4.1+1.1+4.3

15d

+0.4-3.4+3.8-1.6+2.0

-5.4-5.7+0.3-4.7-0.6

-2.2-4.7+2.5-4.7+2.5

-4.0-4.0-0.0-5.6+1.5

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Piramal Pharma's wholly owned stepdown subsidiary, Piramal Critical Care, Inc. (PCC Inc.), had filed a Section 9 Insolvency and Bankruptcy Code (IBC) petition against Astral SteriTech Private Limited (a Centrient Pharmaceuticals subsidiary) before the NCLT Ahmedabad. The NCLT has approved a Resolution Plan under Sections 30 and 31 of the IBC. PCC Inc. has now received an aggregate settlement amount of USD 2,424,334.15 (approximately ₹20 crore) in full settlement of its claim. A closure report will be filed by the Insolvency Professional with IBBI, marking the conclusion of the insolvency process.

Likely market impact

Positive for shareholders — the company has successfully recovered its dues from the counterparty through the IBC process, and the legal matter is now being formally closed, eliminating any further uncertainty or legal overhang from this dispute.